Delivery systems for intraocular routes

Advanced Drug Delivery Reviews

Volumn 16, Issue 1, 1995, Pages 107-123

  Peyman, Gholam A ^a   Ganiban, Gary J ^a  

^a LSU EYE CENTER   (United States)

Author keywords

Acquired immunodeficiency syndrome; Biodegradable implantable device; Cytomegalovirus retinitis; Endophthalmitis; Intravitreal injection; Liposome; Microsphere; Polymer; Proliferative vitreoretinopathy; Sustained release

Indexed keywords

BIODEGRADATION; COMPOSITION EFFECTS; DISEASES; DRUG INTERACTIONS; DRUG PRODUCTS; DRUG THERAPY; IMPLANTS (SURGICAL); OPHTHALMOLOGY; TOXICITY; VISION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIODEGRADABLE IMPLANTABLE DEVICE; CYTOMEGALOVIRUS RETINITIS; ENDOPHTHALMITIS; INTRAVITREAL DRUG DELIVERY; PROLIFERATIVE VITREORETINOPATHY; SUSTAINED RELEASE;

CONTROLLED DRUG DELIVERY;

AMIKACIN; AMPHOTERICIN B METHYL ESTER; CHLORAMPHENICOL; CLINDAMYCIN; DEXAMETHASONE; ETHYLENE VINYL ACETATE COPOLYMER; FLUOROURACIL; FOSCARNET; GANCICLOVIR; GENTAMICIN; IMIPENEM; LINCOMYCIN; LIPOSOME; METICILLIN; MICROSPHERE; NETILMICIN; OXACILLIN; PENICILLIN G; POLYMER; POLYSULFONE; POLYVINYL ALCOHOL; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

BIODEGRADATION; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; ENDOPHTHALMITIS; EYE DISEASE; HUMAN; IMPLANT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; OSMOTIC MINIPUMP; PHARMACEUTICS; PRIORITY JOURNAL; RESERVOIR; RETINITIS; REVIEW; SUSTAINED RELEASE PREPARATION; TOPICAL DRUG ADMINISTRATION; UVEITIS; VITREORETINOPATHY; VITREOUS BODY;

EID: 0029347573     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00018-3     Document Type: Review

References (141)

1. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS
2. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy
3. Intravitreal sustained-release ganciclovir
4. Intravitreal toxicity of hydroxyacyclovir (BW-B759U), a new antiviral agent
5. Prophylaxis and treatment of endophthalmitis
6. Postoperative infections in an ophthalmologic hospital: with comments upon bacteriophage typing of staphylococci as a preventative tool
7. Bacterial endophthalmitis after cataract extraction: a study of 22 infections in 20,000 operations
8. Postoperative complications of cataract extraction
9. Endogenous bacterial endophthalmitis: report of a ten-year retrospective study
10. Bacterial endophthalmitis after cataract surgery
11. Post-operative intra-ocular infection
12. Late infection of filtering conjunctival scars
13. Late infection of filtration blebs
14. Ocular tissue absorption of gentamicin
15. Ocular kinetics of extended duration fluorometholone (0.1%) formulations vs ointment and aqueous suspension
16. Evaluation of ophthalmic suspension containing pilocarpine microcapsules: pharmacodynamic and pharmacokinetic studies
17. Improved performance of ocular drugs formulated in submicron emulsions
18. Collagen shields enhanced penetration of topical cyclosporin
19. Aqueous humor assays of subconjunctival anti-biotics
20. A study of aqueous and serum levels of ceftazidime following subconjunctival administration
21. Treatment of late endophthalmitis associated with filtering blebs
22. Experiences with five cases of postoperative endophthalmitis
23. The intravitreal penetration of ceftriaxone in man following systemic administration
24. Penetration of imipenem into human aqueous and vitreous humor
25. Distribution of penicillin in the eye after injections of 1000000 units of the subconjunctival retrobulbar and intramuscular routes
26. Bacterial endophthalmitis: treatment with intraocular injection of gentamicin and dexamethasone
27. Clinical use of intravitreal antibiotics to treat bacterial endophthalmitis
28. Drug therapy for endophthalmitis
29. Exogenous endophthalmitis initially treated without systemic antibiotics
30. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus
31. Intravitreal drug therapy
32. Experimental study on penicillin treatment of ectogenous infection of vitreous
33. Controversial points in penicillin therapy for ocular diseases
34. Intravitreal penetration of penicillin and penicillin therapy of infections of the vitreous
35. Penicillin and the control of deep intra-ocular infection
36. Treatment of late postoperative intraocular infections with intraocular injection of penicillin
37. Intraocular injection of gentamicin: toxic effects and clearance
38. Intraocular injection of gentamicin: single injection therapy of experimental bacterial endophthalmitis
39. Toxicity of intravitreal injection of amphotericin B
40. Intravitreal amphotericin B treatment of experimental fungal endophthalmitis
41. Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis
42. Intravitreal injection of cephaloridine in the treatment of endophthalmitis
43. Intraocular chloramphenicol and bacterial endophthalmitis
44. Intravitreal injection of kanamycin in experimentally induced endophthalmitis
45. BB-K8: a new aminoglycoside for intravitreal injection in bacterial endophthalmitis
46. Use of tobramycin in eradicating experimental bacterial endophthalmitis
47. Lincomycin by direct intravitreal injection in the treatment of experimental bacterial endophthalmitis
48. Toxicity of intravitreal aminoglycosides in primates
49. The intravitreal use of carbenicillin (Geopen) for treatment of Pseudomonas endophthalmitis
50. Intravitreal clindamycin phosphate in the treatment of vitreous infection
51. Comparative toxicity of intravitreal aminoglycoside antibiotics
52. Aminoglycoside toxicity
53. Intravitreal injection of penicillin in case of incipient abscess of the vitreous following extracapsular cataract extraction: perfect cure: report of a case
54. Intravitreal cephalothin in experimental staphylococcal endophthalmitis
55. Toxicity, efficacy, and clearance of intravitreally injected cefazolin
56. Pharmacokinetic analysis of intravitreal ceftriaxone in monkeys
57. Intravitreal ceftriaxone in a rabbit model: dose- and time-dependent toxic effects and pharmacokinetic analysis
58. Intravitreal ceftazidime in a rabbit model: Dose-and time-dependent toxicity and pharmacologic analysis
59. Intravitreal erythromycin in the treatment of induced staphylococcal endophthalmitis
60. The intraocular penetration of lincomycin
61. Intravitreal injection of vancomycin in experimental staphylococcal endophthalmitis
62. Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence for resistance to ‘late’ treatment of infections
63. Successful treatment of Candida albicans endophthalmitis with intravitreal amphotericin B
64. Staphylococcus epidermidis endophthalmitis: visual outcome following noninvasive therapy
65. Cytomegalovirus retinitis and response to therapy with ganciclovir
66. Cytomegalovirus retinopathy as the initial manifestation of the acquired immunodeficiency syndrome
67. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection experience in 314 immunocompromised patients
68. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome
69. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet)
70. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
71. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet-ganciclovir Cytomegalovirus retinitis trial 4 visual outcome
72. Intraocular 9-( [2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine levels after intravitreal and subconjunctival administration
73. Treatment of cytomegalovirus retinopathy with ganciclovir
74. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis
75. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome
76. The classification of retinal detachment with proliferative vitreoretinopathy
77. Inhibition of intraocular proliferations with intravitreal corticosteroids
78. Fluorouracil for the treatment of massive periretinal proliferation
79. 5-Fluorouracil: new applications in complicated retinal detachment for an established antimetabolite
80. Ocular toxicity of fluorouracil after vitrectomy
81. Fluorouridine: a second generation ocular antimetabolite
82. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy: control by daunomycin
83. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation
84. Inhibition of experimental intraocular proliferation with intravitreal 5-fluorouracil
85. Toxicity of antineoplastic drug combinations in vitrectomy infusion fluid
86. Retinal atrophy induced by intravitreous colchicine
87. Taxol for the treatment of proliferative vitreoretinopathy
88. Pharmacological modulation of human subconjunctival fibroblast behavior in vitro
89. Membrane models with phospholipids
90. Liposomes as a drug delivery system
91. Liposomes in topical drug delivery
92. Idoxuridine-liposome therapy for herpes simplex keratitis
93. 125 I-labelled idoxuridine liposome
94. Pharmacokinetics of subconjunctival liposome-encapsulated gentamicin in normal rabbit eyes
95. Liposomes as a drug delivery system
96. Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis
97. Liposomes in topical drug delivery
98. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin
99. Liposomes as carriers of antimicrobial agents
100. 99mTc-labeled liposomes in patients with cancer
101. Multivesicular liposomes: sustained release of the antimetabolite cytarabine in the eye
102. Ocular drug bioavailability from topically applied liposomes
103. Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model
104. Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys
105. Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits
106. Intravitreal liposome-encapsulated gentamicin in a rabbit model: prolonged therapeutic levels
107. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model
108. Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug
109. Intravitreal liposome-encapsulated drugs: a preliminary human report
110. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model
111. Microencapsulation of anticancer drug for intraarterial infusion and its clinical application
112. Lactic acid oligomer microspheres containing an anticancer agent for selective lymphatic delivery. I. In vitro studies
113. Biodegradable microspheres for prolonged anesthesia
114. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres
115. Poly(DL-lactide-co-glycolide) norethisterone microcapsules: an injectable biodegradable contraceptive
116. Sustained release of an antimalarial drug containing a copolymer of glycolic/lactic acid
117. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous
118. Biodegradable microspheres containing Adriamycin in the treatment of proliferative vitreoretinopathy
119. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR
120. Injectable microspheres with controlled drug release for glaucoma filtering surgery
121. Clearance of fluorescein incorporated into microspheres from the cornea and aqueous after subconjunctival injection
122. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection
123. Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates
124. Externally triggered release of dye and drugs from liposomes into the eye: an in vitro and in vivo study
125. Feasibility of blood flow measurement by externally controlled dye delivery
126. Measurement of retinal blood velocity and flow rate in primates using a liposome-dye system
127. Experimental endophthalmitis treated with an implantable osmotic minipump
128. An ocular perfusion system
129. A method for chronic drug infusion into the eye
130. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device
131. Treatment of cytomegalovirus retinitis with an intraocular sustained-elease ganciclovir implant: a randomized controlled clinical trial
132. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
133. Ganciclovir intraocular device and patient survival
134. Evaluation of a slow-release daunomycin implant for experimental PVR: simultaneous pharmacokinetic and pharmacodynamic evaluations
135. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations
136. Sustained release of 5-FU from biodegradable-matrix delivery for intraocular application: in vitro and in vivo evaluations
137. Low molecular weight poly(caprolactone) and poly(DL-lactide) prepared by hydrolysis and their applications as biodegradable carriers for drug delivery
138. Bioerodible ganciclovir delivery system for intraocular application in vitro: kinetic evaluation
139. Scleral plug of biodegradable polymer for controlled drug release in the vitreous